Antithrombotics in stable peripheral artery disease

Vascular Medicine
Eric KaplovitchSonia S Anand

Abstract

Patients with peripheral artery disease (PAD) are at high risk for ischemic cardiovascular complications. While single antiplatelet therapy (SAPT), predominantly aspirin, has long been the standard antithrombotic treatment in stable PAD, there have now been greater than 40,000 PAD patients randomized to varying antiplatelet and/or anticoagulant regimens. In this review, we provide a summary of the current evidence for antithrombotics in stable PAD, focusing on the rates of major adverse cardiovascular events (MACE), major adverse limb events (MALE), and major bleeding. SAPT has a limited role in the treatment of asymptomatic PAD, particularly in the absence of concomitant coronary artery disease. In symptomatic PAD, SAPT is effective in preventing MACE, though treatment with a thienopyridine appears marginally superior to aspirin. Dual antiplatelet therapy (DAPT) suggests benefit over SAPT in reducing MACE and MALE, though studies to date are not conclusive and/or are associated with excess major bleeding. Combining moderate to high intensity vitamin K antagonists with antiplatelet therapy does not reduce MACE or MALE and increases life-threatening bleeding. Rivaroxaban 2.5 mg BID in addition to aspirin reduces the incidence of...Continue Reading

References

Sep 16, 1998·Journal of Vascular Surgery·T P SaracJ M Seeger
Aug 25, 2001·The New England Journal of Medicine·S YusufUNKNOWN Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators
Mar 20, 2003·Journal of the American College of Cardiology·Sonia S Anand, Salim Yusuf
Mar 15, 2006·The New England Journal of Medicine·Deepak L BhattUNKNOWN CHARISMA Investigators
Feb 20, 2007·Journal of Internal Medicine·UNKNOWN Critical Leg Ischaemia Prevention Study (CLIPS) GroupR Peto
Mar 22, 2007·JAMA : the Journal of the American Medical Association·Ph Gabriel StegUNKNOWN REACH Registry Investigators
Jul 20, 2007·The New England Journal of Medicine·UNKNOWN Warfarin Antiplatelet Vascular Evaluation Trial InvestigatorsGilbert Gosselin
Apr 19, 2008·Journal of the American College of Cardiology·Gijs M J M WeltenDon Poldermans
Jul 10, 2008·JAMA : the Journal of the American Medical Association·UNKNOWN Ankle Brachial Index CollaborationM M McDermott
Jan 13, 2009·European Heart Journal·Patrice P CacoubUNKNOWN CHARISMA Investigators
May 14, 2009·JAMA : the Journal of the American Medical Association·Jeffrey S BergerWilliam R Hiatt
Sep 1, 2009·The New England Journal of Medicine·Lars WallentinMona Thorsén
Mar 4, 2010·JAMA : the Journal of the American Medical Association·F Gerald R FowkesUNKNOWN Aspirin for Asymptomatic Atherosclerosis Trialists
Sep 2, 2010·JAMA : the Journal of the American Medical Association·Deepak L BhattUNKNOWN REACH Registry Investigators
Nov 15, 2011·The New England Journal of Medicine·Jessica L MegaUNKNOWN ATLAS ACS 2–TIMI 51 Investigators
Mar 23, 2012·Circulation·Marco ValgimigliUNKNOWN Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators
Mar 27, 2012·The New England Journal of Medicine·David A MorrowUNKNOWN TRA 2P–TIMI 50 Steering Committee and Investigators
Sep 18, 2012·Annals of Vascular Surgery·Matthew T AllemangVikram S Kashyap
Feb 12, 2013·Stroke; a Journal of Cerebral Circulation·David A MorrowUNKNOWN Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events–TIMI 50 Steering Committee and Inve
Mar 7, 2013·JAMA : the Journal of the American Medical Association·Peng Foo WongGerard Stansby
Nov 18, 2014·The New England Journal of Medicine·Laura MauriUNKNOWN DAPT Study Investigators
Mar 17, 2015·The New England Journal of Medicine·Marc P BonacaUNKNOWN PEGASUS-TIMI 54 Steering Committee and Investigators
Apr 6, 2016·Journal of the American College of Cardiology·Marc P BonacaMarc S Sabatine
Dec 14, 2016·The New England Journal of Medicine·William R HiattUNKNOWN EUCLID Trial Steering Committee and Investigators
May 6, 2017·JACC. Cardiovascular Interventions·Eric A SecemskyUNKNOWN Dual Antiplatelet Therapy Study Investigators
Aug 29, 2017·The New England Journal of Medicine·John W EikelboomUNKNOWN COMPASS Investigators
Mar 16, 2018·Journal of the American College of Cardiology·Sonia S AnandSalim Yusuf

❮ Previous
Next ❯

Citations

Mar 12, 2021·Current Cardiology Reports·Graham R McClureSonia S Anand

❮ Previous
Next ❯

Methods Mentioned

BETA
amputation
peripheral artery bypass
amputations

Software Mentioned

CHARISMA
PRODIGY
PEGASUS
PAD
COMPASS

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.